Tag: CSE:PREV
April 17, 2019
PreveCeutical Partnership Leads to Two New Patent Filings
PreveCeutical Medical Inc. (CSE:PREV) (OTCQB PRVCF) (FSE:18H) (the "Company" or "PreveCeutical") announces that the Company's research collaboration with UniQuest and The University of... April 15, 2019
PreveCeutical Files Application to Human Ethics Committee to Acquire Human Tissue for the Final Phase of the Sol-Gel Program
PreveCeutical Medical Inc. (CSE:PREV, OTCQB:PRVCF, FSE:18H) (the "Company" or "PreveCeutical"), announces the Company's research team at the University of Queensland... April 10, 2019
PreveCeutical Announces Further Results from its Preliminary Screening of Peptides Derived from Blue Scorpion Venom in a Cell-Based Brain Cancer Model
PreveCeutical Medical Inc. (CSE:PREV, OTCQB:PRVCF, FSE:18H)(the "Company" or "PreveCeutical"), is pleased to announce further positive results from the preliminary screening... April 8, 2019
PreveCeutical Announces Default Judgment Against JCN Capital Corp.
PreveCeutical Medical Inc. (CSE:PREV, OTCQB:PRVCF, FSE:18H)(the "Company" or "PreveCeutical"), announces that it has obtained a default judgement against JCN Capital... April 4, 2019
Retraction to News Release dated April 4, 2019
PreveCeutical Medical Inc. (CSE:PREV) (OTCQB:PRVCF) (FSE:18H) (the "Company" or "PreveCeutical"), announces that, at the request of the Investment Industry Regulatory Organization...
April 4, 2019
Asterion Welcomes Australian Government Awarding of Major Project Status for its Toowoomba Medicinal Cannabis Project
Asterion Cannabis Inc. (P.ASTR) ("Asterion") and PreveCeutical Medical Inc. ("PreveCeutical") (CSE:PREV) (OTCQB:PRVCF) (FSE:18H), announce today that Asterion's wholly-owned Australian subsidiary, Asterion Australia Pty Ltd,...
March 25, 2019